Opinions of African American adults about the use of apolipoprotein L1 (ApoL1) genetic testing in living kidney donation and transplantation
| Autor: | Jasmine Austrie, Margaret T. Berrigan, Prabhakar K. Baliga, Thomas Hugh Feeley, Kenneth P. Tercyak, James R. Rodrigue, Aaron Fleishman, Vinayak Rohan, Liise K. Kayler, Martin R. Pollak, Martha Pavlakis |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Apolipoprotein L1 030230 surgery Kidney Article 03 medical and health sciences 0302 clinical medicine Internal medicine Immunology and Allergy Medicine Humans Pharmacology (medical) Genetic Testing Genetic testing Aged Transplantation medicine.diagnostic_test biology business.industry Odds ratio medicine.disease Kidney Transplantation Confidence interval Black or African American Donation biology.protein business Kidney disease Patient education |
| Zdroj: | Am J Transplant |
| ISSN: | 1600-6143 |
| Popis: | Apolipoprotein L1 (ApoL1) predictive genetic testing for kidney disease, and its emerging role in transplantation, remains controversial as it may exacerbate underlying disparities among African Americans (AAs) at increased risk. We conducted an online simulation among AAs (N = 585) about interest in ApoL1 testing and its cofactors, under 2 scenarios: as a potential living donor (PLD), and as a patient awaiting transplantation. Most respondents (61%) expressed high interest in genetic testing as a PLD: age ≥35 years (adjusted odds ratio [aOR], 1.75; 95% confidence interval [CI], 1.18, 2.60, P = .01), AA identity (aOR, 1.67; 95% CI, 1.02, 2.72, P = .04), perceived kidney disease risk following donation (aOR, 1.68; 95% CI, 1.03, 2.73, P = .03), interest in genetics (aOR, 2.89; 95% CI, 1.95, 4.29, P = .001), and genetics self-efficacy (aOR, 2.38; 95% CI, 1.54, 3.67, P = .001) were positively associated with ApoL1 test interest. If awaiting transplantation, most (89%) believed that ApoL1 testing should be done on AA deceased donors, and older age (aOR, 1.85; 95% CI, 1.03, 3.32, P = .04) and greater interest in genetics (aOR, 2.61; 95% CI, 1.41, 4.81, P = .002) were associated with interest in testing deceased donors. Findings highlight strong support for ApoL1 testing in AAs and the need to examine such opinions among PLDs and transplant patients to enhance patient education efforts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text